High Prevalence of Vitamin D Inadequacy and Implications for Health

Slides:



Advertisements
Similar presentations
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Advertisements

Endocrine Regulation of Calcium and Phosphate Metabolism
CALCIUM AND PHOSPHATE HOMEOSTASIS. Organs: Parathyroid Four oval masses on posterior of thyroid gland Develops from the 3 rd and 4 th pharyngeal pouches.
Pharmacology of drugs used in calcium & vitamin D disorders
Vitamin D, Rickets and Osteoporosis
Pharmacology of drugs used in calcium & vitamin D disorders
Vitamin D, Rickets and Osteoporosis
Vitamin D: Is It A Miracle Cure? Robert Coleman, M.D, F.A.C.E. Cotton-O'Neil Diabetes & Endocrinology Topeka, KS.
DR. MOHAMMED AL DUBAYEE, MD, MHSC, CDE ASSISTANT PROFESSOR, PEDIATRIC ENDOCRINOLOGIST KAMC- RIYADH VTI D BONE AND BEYOND ; WHEN TO SCREEN, WHOM TO TREAT?
Daniel Bikle, John Adams, and Sylvia Christakos
Volume 68, Pages S24-S28 (July 2005)
Vitamin D Inadequacy is Highly Prevalent Among North American Women Treated for Osteoporosis MF Holick1, ES Siris2, N Binkley3, MK Beard4, AA Khan5, JT.
Redefining vitamin D insufficiency
Pharmacology of drugs used in calcium & vitamin D disorders
The Physiology and Pathophysiology of Vitamin D
Therapeutic Implications
Volume 79, Pages S3-S8 (April 2011)
Vitamin D3 Presented by John Lear.
Pharmacology of drugs used in calcium & vitamin D disorders
Vitamin D metabolism and physiologic effects at target organs
Vitamin D is a group of fat-soluble secosteroids responsible for intestinal absorption of calcium and phosphate. It is not actually an essential dietary.
Volume 67, Pages S1-S7 (June 2005)
High Prevalence of Vitamin D Inadequacy and Implications for Health
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Vitamin D Insufficiency
Vitamin D for Health: A Global Perspective
Osteoporosis in Individuals with Spinal Cord Injury
Agents That Affect Bone Mineral Homeostasis
The Physiology and Pathophysiology of Vitamin D
Volume 73, Issue 1, Pages 3-5 (January 2008)
Diagnosis and Management of Chronic Kidney Disease
Fibroblast Growth Factor 23 and CKD Prognosis
Renal vitamin D receptor expression and vitamin D renoprotection
Intern Seminar: Vitamin D deficiency
Phosphorus Nutrition and the Treatment of Osteoporosis
Maternal Vitamin D Supplementation to Improve the Vitamin D Status of Breast-fed Infants: A Randomized Controlled Trial  Sara S. Oberhelman, MD, Michael.
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Phosphorus: Another Devil in Our Diet?
New Vitamin D analogs and changing therapeutic paradigms
FGF23 or PTH: which comes first in CKD ?
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Ergocalciferol and Cholecalciferol in CKD
Volume 78, Issue 10, Pages (November 2010)
Palliative Care and Hospice Programs
FGF23–parathyroid interaction: implications in chronic kidney disease
Role of vitamin D in uterine fibroid biology
Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation  Adriana S. Dusso  Kidney International Supplements 
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Chapter 3: Management of progression and complications of CKD
Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study  Daniel V. Dudenkov, MD, Barbara P. Yawn, MD,
Graphic Interpretation of Serum Parathyroid Hormone, Calcium, and Phosphorus Values in Primary Hyperparathyroidism  Pai C. Kao, Ph.D., Edward G. Lufkin,
Volume 79, Pages S20-S23 (April 2011)
Volume 66, Pages S25-S32 (September 2004)
Vitamin D: The Iceberg Nutrient
Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1α-hydroxylase  Mutsuko Ohnishi, Teruyo.
Volume 67, Pages S33-S36 (June 2005)
Vitamin D receptor: A highly versatile nuclear receptor
Volume 68, Pages S24-S28 (July 2005)
The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.
Phosphate and the parathyroid
Volume 71, Issue 8, Pages (April 2007)
Recent developments in the management of secondary hyperparathyroidism
The ins and outs of phosphate homeostasis
Control of uremic bone disease: Role of vitamin D analogs
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Volume 82, Issue 1, Pages (July 2012)
Volume 64, Pages S131-S136 (November 2003)
Regulation of serum calcium homeostasis.
Presentation transcript:

High Prevalence of Vitamin D Inadequacy and Implications for Health Michael F. Holick, PhD, MD  Mayo Clinic Proceedings  Volume 81, Issue 3, Pages 353-373 (March 2006) DOI: 10.4065/81.3.353 Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Cutaneous production of vitamin D and its metabolism and regulation for calcium homeostasis and cellular growth. 7-Dehydrocholesterol or provitamin D3 (proD3) in the skin absorbs solar UV-B radiation and is converted to previtamin D3 (preD3). D3 undergoes thermally induced (δH) transformation to vitamin D3. Vitamin D from the diet or from the skin is metabolized in the liver by the vitamin D-25-hydroxylase to 25-hydroxyvitamin D3 (25[OH]D3). 25(OH)D3 is converted in the kidney by the 25(OH)D3-1α-hydroxylase to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. A variety of factors, including serum phosphorus (PO2−4) and parathyroid hormone (PTH), regulate the renal production of 1,25(OH)2D3. 1,25(OH)2D regulates calcium metabolism through its interaction with its major target tissues, the bone and the intestine. From Osteoporos Int,21 with permission from Springer Science and Business Media. Mayo Clinic Proceedings 2006 81, 353-373DOI: (10.4065/81.3.353) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Left, Relationship between serum 25-hydroxyvitamin D (25[OH]D) concentrations and mean ± SE (error bars) serum concentrations of parathyroid hormone in patients with osteoporosis receiving treatment. Right, Percentage of subjects with secondary hyperparathyroidism by 25(OH)D level. The percentage of subjects with secondary hyperparathyroidism (parathyroid hormone level >40 pg/mL) sorted by subgroups with serum 25(OH)D concentrations delineated by predefined cutoffs for analyses of 25(OH)D inadequacy. Left and right, From J Endocrinol Metab,30 with permission from The Endocrine Society, Copyright 2005. Mayo Clinic Proceedings 2006 81, 353-373DOI: (10.4065/81.3.353) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Mean ± SD (error bars) serum 25-hydroxyvitamin D (25[OH]D) concentrations (shown as nmol/L and ng/mL) in women older than 70 years, stratified by supplement use and residential status. Adapted from J Clin Endocrinol Metab,97 with permission from The Endocrine Society, Copyright 1988. Mayo Clinic Proceedings 2006 81, 353-373DOI: (10.4065/81.3.353) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 4 Relative to therapy with 1200 mg/d of calcium for 12 weeks, daily therapy with 800 IU of vitamin D and 1200 mg of calcium accounted for a 49% reduction in the relative risk of falls among older women (mean age, 85.3 years) in long-term geriatric care. Ca = calcium; Ca + D = Ca plus vitamin D. Adapted from J Bone Miner Res,174 with permission from The American Society for Bone and Mineral Research. Mayo Clinic Proceedings 2006 81, 353-373DOI: (10.4065/81.3.353) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 5 Endocrine and autocrine or paracrine functions of 1,25-dihydroxyvitamin D (1,25[OH]2D). The kidneys serve as the endocrine organ to convert 25-hydroxyvitamin D (25[OH]D) to 1,25(OH)2D. 1,25(OH)2D carries out its calcium-regulating functions for bone health by stimulating intestinal calcium and phosphorus absorption. The circulating levels of 1,25(OH)2D can also potentially influence the activity of other tissues and cells that have a vitamin D receptor (VDR) and have no function in regulating calcium homeostasis and bone health. These include, among others, the heart skeletal muscle, active T and B lymphocytes, breast, colon, and prostate. In addition, a multitude of in vitro studies with human and animal cells have shown that most tissues and cells not only express the VDR but also express the same 1α-hydroxylase as the kidney. Thus, it has been suggested that most cells, including lung, colon, prostate, and breast, locally produce 1,25(OH)2D3 to help regulate a variety of cellular functions including growth and differentiation. This may help explain the epidemiological evidence that sun exposure at lower altitudes and higher serum levels of 25(OH)D are related to a decreased risk of a wide variety of chronic illnesses. It has been speculated that when 25(OH)D levels are above 30 ng/mL this serves as the substrate for the external 25(OH)D3-1α-hydroxylase to produce 1,25(OH)2D in the colon, prostate, breast, and lung to modulate cell growth and reduce risk of the cells becoming malignant. Mayo Clinic Proceedings 2006 81, 353-373DOI: (10.4065/81.3.353) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions